We have previously demonstrated that an intact PSAP motif in the ORF3 protein is required for the formation and release of membrane-associated hepatitis E virus (HEV) particles with ORF3 proteins on their surface. In this study, we investigated the direct interaction between the ORF3 protein and tumour susceptibility gene 101 (Tsg101), a cellular factor involved in the budding of viruses containing the P(T/S)AP late-domain, in PLC/PRF/5 cells expressing the wild-type or PSAP-mutated ORF3 protein and Tsg101 by co-immunoprecipitation. Tsg101 bound to wildtype ORF3 protein, but not to the PSAP-inactive ORF3 protein. To examine whether HEV utilizes the multivesicular body (MVB) pathway to release the virus particles, we analysed the efficiency of virion release from cells upon introduction of small interfering RNA (siRNA) against Tsg101 or dominant-negative (DN) mutants of Vps4 (Vps4A and Vps4B). The relative levels of virus particles released from cells depleted of Tsg101 decreased to 6.4 % of those transfected with negative control siRNA. Similarly, virion egress was significantly reduced by the overexpression of DN forms (Vps4AEQ or Vps4BEQ). The relative levels of virus particles released from cells expressing Vps4AEQ and Vps4BEQ were 19.2 and 15.6 %, respectively, while the overexpression of wildtype Vps4A and Vps4B did not alter the levels of virus release. These results indicate that the ORF3 protein interacts with Tsg101 through the PSAP motifs in infected cells, and that Tsg101 and the enzymic activities of Vps4A and Vps4B are involved in HEV release, thus suggesting that HEV requires the MVB pathway for egress of virus particles.
INTRODUCTION
Hepatitis E virus (HEV), a member of the genus Hepevirus in the family Hepeviridae, is the causative agent of acute or fulminant hepatitis E, which occurs in many parts of the world, principally as a water-borne infection in developing countries and zoonotically in industrialized countries (Chandra et al., 2008; Colson et al., 2010; Dalton et al., 2008; Purcell & Emerson, 2008; Tei et al., 2003; Yazaki et al., 2003) . HEV is a non-enveloped small virus with a diameter of 27-32 nm, present in the bile and faeces of infected hosts, while HEV particles in the circulating blood and culture supernatant are found to be associated with lipids (Takahashi et al., 2008b (Takahashi et al., , 2010 Yamada et al., 2009a) . The HEV genome is a positive-sense, ssRNA composed of approximately 7200 nt, which is capped and polyadenylated (Kabrane-Lazizi et al., 1999; Tam et al., 1991) . The genome consists of a 59 UTR, three ORFs, a 39 UTR and a poly(A) tail at the 39 terminus (Emerson & Purcell, 2007) . ORF1 encodes non-structural proteins including a methyltransferase, papain-like cysteine protease, helicase and RNA-dependent RNA polymerase (Agrawal et al., 2001; Koonin et al., 1992) . ORF2 and ORF3 overlap, and the ORF2 and ORF3 proteins are translated from a bicistronic subgenomic RNA 2.2 kb in length (Graff et al., 2006; Ichiyama et al., 2009) . The ORF2 protein is the viral capsid protein of 660 aa, while the ORF3 protein is a small protein of only 113 or 114 aa, which has been suggested to act as an adaptor to link the intracellular transduction pathways, reduce the host inflammatory response and protect virus-infected cells (Chandra et al., and responsible for sporadic cases worldwide (Okamoto, 2007) . A number of animal strains of HEV have also been identified from several animal species including chickens, pigs and wild boars (Meng, 2011) .
The class E vacuolar protein sorting (Vps) pathway functions at the limiting membrane of multivesicular bodies (MVBs) during lumenal vesicle formation, and is exploited by the late assembly or L-domains of enveloped viruses during budding (Katzmann et al., 2002; Pornillos et al., 2002) . Many class E Vps factors are components of three endosomal sorting complexes required for transport (ESCRT-I, -II and -III) (Babst et al., 2002a, b; Katzmann et al., 2001) . A current model for viral and MVB vesicle budding invokes the sequential recruitment of ESCRT-I, -II and -III. Thereafter, budding occurs concurrently with the release of ESCRT components from the MVB membrane induced by an AAA-ATPase, Vps4, which is present in humans as two isoforms, Vps4A and Vps4B (Babst et al., 1998; Katzmann et al., 2002) . Numerous enveloped RNA viruses such as human immunodeficiency virus type 1 (HIV-1) (Garrus et al., 2001) , Ebola virus (Martin-Serrano et al., 2001 ) and avian sarcoma virus (ASV) (Pincetic et al., 2008) and, more recently, hepatitis C virus (HCV) (Ariumi et al., 2011; Corless et al., 2010; Lai et al., 2010) have been shown to utilize ESCRT complexes during virion morphogenesis. Furthermore, enveloped DNA viruses including hepatitis B virus (HBV) (Lambert et al., 2007; Watanabe et al., 2007) and herpes simplex virus 1 (HSV-1) (Crump et al., 2007) have been reported to exploit the MVB machinery.
Known late domains consist of the amino acid sequence P(T/ S)AP, PPxY or YxxL, where 'x' represents any amino acid (Göttlinger et al., 1991; Huang et al., 1995; Wills & Craven, 1991; Yasuda & Hunter, 1998) . The PTAP motifs recruit ESCRT-I by binding to Tsg101 (Demirov et al., 2002; Garrus et al., 2001; Martin-Serrano et al., 2001; VerPlank et al., 2001) . Tsg101 is a component of ESCRT-I, a cellular complex essential in the Vps pathway, which traffics proteins to the MVB and lysosome (Bishop & Woodman, 2001; Katzmann et al., 2001) . Small interfering RNA (siRNA)-mediated Tsg101 depletion potently blocks HIV-1 release (Garrus et al., 2001) . Moreover, all late domain (L-domain) types require a subset of class E Vps factors, and their function is blocked by dominant-negative (DN) forms of ESCRT-III components (Martin-Serrano et al., 2003a; Strack et al., 2003; von Schwedler et al., 2003) or Vps4 (Garrus et al., 2001; Martin-Serrano et al., 2003b; Tanzi et al., 2003) .
The PSAP motif between amino acid residues 95 and 98 of the ORF3 protein was found to be conserved among all known HEV strains of genotypes 1-4 and avian HEV strains (Nagashima et al., 2011) . Surjit et al. (2006) reported that cellular Tsg101 binds to the PSAP motif located within the ORF3 protein, and that substitutions in the PSAP sequence abolish the ability of the protein to bind Tsg101. In our previous study, we demonstrated that the PSAP motif(s) in the ORF3 protein is necessary for the egress of HEV particles from infected cells, and proposed that the PSAP motifs in the ORF3 protein play a role as the functional domain required for virion release associated with lipids and the ORF3 protein (Nagashima et al., 2011) . However, it remains unclear whether the MVB pathway is involved in HEV virion egress. In this study, we investigated the requirement of Tsg101 and Vps4 during the release of viral particles by using siRNA against Tsg101 and DN mutants of Vps4. The results showed that Tsg101 and the enzymic activities of Vps4A and Vps4B are involved in the release of HEV virions, thus suggesting that HEV utilizes the MVB machinery to exit cells.
RESULTS
The ORF3 protein interacts with Tsg101 in cultured cells
In our previous study with the advent of co-immunoprecipitation method, we showed that the exogenously expressed wild-type ORF3 protein interacts with endogenous Tsg101 in PLC/PRF/5 cells, and that this interaction is associated with the PSAP motif(s) in the ORF3 protein (Nagashima et al., 2011) . However, endogenous Tsg101 binding to the ORF3 protein was not detected upon immunoprecipitation with an anti-ORF3 mAb, probably because there was insufficient expression of endogenous Tsg101 to permit detection by Western blotting analysis. To confirm the binding of ORF3 protein with Tsg101 in vivo, we investigated the direct interaction between the Tsg101 and ORF3 proteins in cells expressing Tsg101 containing a Myc-tag at its N terminus (Tsg101-Myc) and ORF3 protein by co-immunoprecipitation. The PLC/PRF/5 cells were transfected with pBj-MycTsg101 in combination with pCI-HEVORF3/wt or pCI-HEVORF3/mutPLAP/LSAL, or with both empty vectors. As shown in Fig. 1(a) , the expression of Tsg101-Myc was detectable by Western blotting analysis using anti-Myc mAb (left panel) and anti-Tsg101 mAb (right panel). Similarly, it was found that wild-type and mutPLAP/LSAL ORF3 proteins were efficiently expressed in the transfected cells (Fig. 1b) .
The extracts of the PLC/PRF/5 cells co-transfected with pBjMyc-Tsg101 in combination with pCI-HEVORF3/wt or pCI-HEVORF3/mutPLAP/LSAL were subjected to immunoprecipitation with either the anti-Myc or anti-ORF3 mAb and then the immunoprecipitates were analysed by Western blotting using either anti-Tsg101 or anti-ORF3 mAb. As shown in Fig. 1(c) , the Tsg101-Myc and ORF3 proteins were co-immunoprecipitated with either the antiMyc or the anti-ORF3 mAb in cell extracts expressing the wild-type ORF3 and Tsg101-Myc proteins. In contrast, the cell extracts expressing the mutated ORF3 protein without intact PSAP motifs (mutPLAP/LSAL) and Tsg101-Myc did not show any co-immunoprecipitates of the Tsg101-Myc and ORF3 proteins. As expected, no immunoprecipitates were observed in extracts of cells transfected with both empty vectors, confirming the specificity of the Western blot analysis. These results confirmed that the ORF3 protein interacts with Tsg101 through its PSAP motif in vivo.
Intracellular localization of the ORF3 protein and Tsg101
We subsequently examined the intracellular localization of the ORF3 protein and Tsg101 by immunofluorescence confocal microscopy. First, to confirm the specific detection of the Tsg101-Myc and ORF3 proteins expressed in the transfected cells, PLC/PRF/5 cells were transfected with pBj-Myc-Tsg101, pCI-HEVORF3/wt and pCI-HEVORF3/ mutPLAP/LSAL, or with both the pBj-Myc and pCI vectors (Fig. 2a) . At 48 h after transfection, cells were stained simultaneously with Alexa Fluor 488-conjugated anti-Myc and Alexa Fluor 594-conjugated anti-ORF3 mAbs. The signal of Myc-tagged Tsg101 stained by anti-Myc was visible only in the cytoplasm of cells transfected with pBj-MycTsg101. Similarly, the signals of wild-type and mutant ORF3 proteins detectable by anti-ORF3 were seen in both cells transfected with pCI-HEVORF3/wt and those with pCI-HEVORF3/mutPLAP/LSAL. In contrast, no specific signals were observed in the cells transfected with both empty vectors. These results indicate that there was specific detection of Tsg101-Myc and ORF3 proteins in the expressed cells by the immunofluorescence assay used.
To examine the intracellular co-localization of the ORF3 protein with Tsg101 through its PSAP motif, PLC/PRF/5 cells were transfected with pBj-Myc-Tsg101, along with pCI-HEVORF3/wt or pCI-HEVORF3/mutPLAP/LSAL. At 48 h post-transfection, the cells were fixed and processed for the immunofluorescence assay (Fig. 2b) . At least 20 different cells co-expressing Tsg101-Myc and ORF3 proteins were analysed in two independent experiments. A high degree of co-localization (92.5±2.5 %) of wild-type ORF3 protein and Tsg101 was observed in the cytoplasm. In contrast, the mutPLAP/LSAL ORF3 protein showed essentially no signal of co-localization with Tsg101, despite the fact that the mutated ORF3 protein showed an intracellular localization similar to the wild-type ORF3 protein. These results support the notion that the ORF3 protein interacts with Tsg101 through its PSAP motif in infected cells.
Functional involvement of Tsg101 in virion release
To examine whether Tsg101 is functionally involved in HEV budding through its interaction with the ORF3 protein, we utilized siRNA to deplete Tsg101 and examined its effect on virion release from infected cells. PLC/PRF/5 cells were treated with 5 nM of siRNA specific for Tsg101 (siTsg101) or negative control siRNA (NC siRNA) 2 days before and 4 days after virus inoculation (Fig. 3a) . Two days after the first transfection of siRNA, the treated cells were inoculated with 2.0610 5 copies of cell culture-derived HEV. Transfection of siTsg101, but not NC siRNA and buffer only (no siRNA), caused a marked reduction in the levels of endogenous Tsg101 expression in the inoculated cells (Fig.  3b , day 0). In contrast, no discernible alteration in the expression level of cellular b-actin was observed. The HEV RNA levels in the culture supernatant of cells transfected with NC siRNA or no siRNA increased gradually from 6 days post-inoculation and reached 4.0610 4 and 3.8610 4 copies ml 21 on day 10, respectively ( Fig. 3c) . In sharp contrast, the HEV RNA level in the culture supernatant of the siTsg101-transfected cells increased only slightly on day 10, reaching 2.5610 3 copies ml
21
. The relative levels of virus particles released from cells depleted of Tsg101 were significantly decreased to 6.4 % of that released from cells transfected with NC siRNA. The depletion of endogenous Tsg101 continued at least until day 10, while b-actin was detected at equal levels in both cells transfected with siTsg101 and those transfected with NC siRNA or no siRNA. Next, intracellular viral RNA was serially quantified by two distinct real-time RT-PCR methods with the ORF1 and ORF2/ORF3 probes capable of detecting genomic RNA only (Fig. 3d) and both genomic and subgenomic RNAs (Fig. 3e) , respectively. The HEV RNA level in the siTsg101-transfected cells was similar to those in the cells transfected with or without control siRNA at 1, 4 and 8 days postinoculation, by both of the two distinct quantification methods ( Fig. 3d and e) , suggesting that the HEV RNA replication was not affected by the siTsg101 transfection. These results clearly indicated that Tsg101 plays a pivotal role specifically in the release of HEV virions. It was also strongly suggested that HEV utilizes the mechanism of cellular MVB sorting, since Tsg101 is a component of the ESCRT-I complex that is involved in MVB sorting.
The DN forms of Vps4A and Vps4B inhibit the release of virus particles
To examine the involvement of the MVB sorting pathway in the egress of HEV, we analysed the effects of overexpression of two DN forms of Vps4A and Vps4B that play an essential role at the final step of the MVB sorting pathway, on the virus release. PLC/PRF/5 cells were transfected with 0.5 mg of empty vector or expression plasmids for the DN forms of Vps4A and Vps4B, Vps4AEQ and Vps4BEQ (Urata et al., 2006) , 2 days before and 2 and 6 days after virus inoculation (Fig. 4a) . Two days after the first transfection, the pretreated cells were inoculated with 2.0610 5 copies of HEV progeny in the culture supernatant. As shown in Fig. 4(b) , the expression of Vps4AEQ and Vps4BEQ was seen in the inoculated cells and continued until day 8. The HEV RNA levels in the culture supernatant of cells transfected with the empty vector or buffer only (no plasmid) increased gradually from 6 days post-inoculation and reached 1.0610 4 and 1.1610 4 copies ml 21 on 8 days, respectively (Fig. 4c) . In contrast, the HEV RNA levels in the culture supernatant of cells transfected with Vps4AEQ or Vps4BEQ increased slightly on day 8, with the viral load being 2.2610 3 and 1.8610 3 copies ml
21
, respectively (Fig.  4c) . The relative levels of virus particles released from cells expressing Vps4AEQ and Vps4BEQ were decreased to 19.2 and 15.6 %, respectively, on day 8 (Fig. 4d) . These results suggest that HEV utilizes the Vps pathway for virion egress and that the enzymic activities of Vps4A and Vps4B are involved in virus release.
The effects of overexpression of Vps4A and Vps4B on virion egress
To further investigate the functions of Vps4A and Vps4B, PLC/PRF/5 cells were transfected with pVps4A or pVps4B, 2 days before and 2 and 6 days after virus inoculation (Fig.  4a) . The expression of Vps4A and Vps4B was observed in inoculated cells and continued at least until day 8 (Fig. 4e) . As shown in Fig. 4(f) , the overexpression of Vps4A and Vps4B did not promote or reduce virus release. The relative levels of virus particles released from cells expressing Vps4A and Vps4B were estimated to be 104.3 and 103.7 %, respectively, on day 8 (Fig. 4g) , suggesting that endogenous Vps4 are sufficient for producing viral particles, and that overexpression does not lead to an increased release of viral particles.
Co-localization of the ORF3 protein with CD63
To confirm the intracellular co-localization of the ORF3 protein and MVBs, PLC/PRF/5 cells inoculated with wild-type HEV were fixed and stained simultaneously with Alexa Fluor 594-conjugated anti-ORF3 mAb and Alexa Fluor 488-conjugated antibody against CD63, one of MVB marker proteins (Fig. 5 ). When at least 20 different cells expressing the ORF3 proteins were analysed in two independent experiments, a high degree of co-localization with CD63 (82.5±2.5 %) was observed in the cytoplasm of the infected cells. In support of the specificity of the immunofluorescence assay, no signal of co-localization was visible in the uninfected cells.
DISCUSSION
Our previous study showed the requirement of an intact PSAP motif in the ORF3 protein for the formation and release of membrane-associated HEV particles possessing ORF3 proteins on the surface (Nagashima et al., 2011) , in agreement with the observation by Emerson et al. (2010) who reported that the PxxP motif of the ORF3 protein is important for virus egress and infection. The role of host protein(s) in ORF3-mediated HEV release remained unknown, although the requirement of the PSAP motif suggested a possible role for Tsg101, which was shown to bind the ORF3 protein (Nagashima et al., 2011; Surjit et al., 2006) . In the present study, we confirmed that the ORF3 protein interacts with Tsg101 through a PSAP motif in cultured cells and demonstrated that depletion of endogenous Tsg101 by siRNA led to a significant reduction of HEV release in cultured cells. Furthermore, we demonstrated for the first time that HEV utilizes the Vps machinery to support the release of membrane-associated particles with the ORF3 protein on the surface in a Tsg101-dependent manner. These results indicate that the PSAP motif in the ORF3 protein acts as an L-domain for the release of membrane-associated HEV particles from infected cells.
Efficient release of an enveloped virus requires viral Ldomains, including P(T/S)AP, YxxL and PPxY amino acid motifs, which are found in the structural proteins of enveloped viruses and hijack host proteins in the Vps pathway (Göttlinger et al., 1991; Huang et al., 1995; Wills & Craven, 1991) . This pathway gives rise to MVBs, which are topologically identical to virus budding (Chen & Lamb, 2008) . In the present study, we showed evidence of binding between the PSAP motif of the ORF3 protein and Tsg101, which was found to be essential for the release of HEV virions, since interference with Tsg101 expression by siRNA inhibited the release of HEV (Fig. 3) . This finding indicates an important role for Tsg101 in the release of HEV particles, corroborating the role attributed to Tsg101 in the budding of other known enveloped viruses such as retroviruses (Garrus et al., 2001) , although HEV is a nonenveloped virus.
Since the Vps4 ATPase is one of the final effectors in the Vps pathway and functions downstream of Tsg101, it was hypothesized that DN mutants of Vps4 might disrupt virion release. In fact, DN mutants of Vps4 have been shown to inhibit the budding of infectious HIV-1 particles by more than 200-fold in co-transfection experiments, whereas overexpression of wild-type Vps4 inhibited the budding of HIV-1 by only two-to fourfold (Garrus et al., 2001 ). Our present study indicated that overexpression of Vps4AEQ or Vps4BEQ inhibits the release of HEV, with the relative levels of virus particles released from cells expressing Vps4AEQ and Vps4BEQ being 19.2 and 15.6 % compared with wild-type cells, respectively (Fig. 4) . The reduction in the release of HEV particles in the presence of DN Vps4A or Vps4B appears to be due to a specific block in the formation of membrane-associated virions. It is likely that Vps4 is required for the final step in the formation of membrane-associated HEV particles.
Many enveloped viruses complete their replication cycle by budding from the plasma membrane (Demirov et al., 2002; Hartlieb & Weissenhorn, 2006; Jayakar et al., 2004) . RNA viruses, including HIV and the Ebola virus, utilize the cellular ESCRT machinery to facilitate their escape from host cells by redirecting ESCRT complexes to the cell surface, where they appear to drive the budding and fission of the viral particles (Demirov et al., 2002; Garrus et al., 2001; Martin-Serrano et al., 2003a) . Recently, Lai et al. (2010) reported that HCV egress requires the motility of early to late endosomes, which is microtubule-dependent, and postulated that following the assembly of virus particles in juxtaposition to lipid droplets, the HCV particles are transported through early to late endosomes to the plasma membrane, where the membrane of late endosomes is fused with the plasma membrane to release virions into the extracellular milieu. In most herpesviruses, nucleocapsids with tegument proteins are known to bud into intracellular vesicles formed in the infected cells, which are thought to be derived from the Golgi apparatus, trans-Golgi network (TGN) or endosomes (Crump et al., 2007; Fraile-Ramos et al., 2007) , and the virions are then released into the extracellular environment together with small vesicles by the exosomal secretion pathway.
It remains unknown whether the membrane-associated HEV particles are generated intracellularly or at the cell surface (Ahmad et al., 2011) . HEV particles with lipid membranes and the ORF3 protein on their surface were found abundantly in the lysates of cells infected with wildtype HEV (S. Nagashima and H. Okamoto, unpublished observations), and the ORF3 protein and Tsg101 were colocalized in the cytoplasm (Fig. 2) , thus suggesting that mature membrane-associated HEV particles are generated before their release from the surface of infected cells. The immunofluorescence assay using anti-ORF3 mAb and antibody against CD63, another MVB marker protein, revealed that the ORF3 protein is co-localized with CD63 in the HEV-infected cells (Fig. 5) . Taken altogether, these findings indicate that it is likely that HEV utilizes the cellular ESCRT machinery in the cytoplasm, but not at the cell surface, to induce the release from infected cells. Further studies are needed to clarify whether membrane-associated HEV particles really bud into the intracellular vesicles formed in infected cells, and whether they are derived from the Golgi apparatus, TGN or endosomes, and also whether the mature virions are released into the extracellular environment by the exosomal secretion pathway, similar to known enveloped viruses such as HCV (Crump et al., 2007; Fraile-Ramos et al., 2007; Lai et al., 2010) .
A conserved enveloped virus release mechanism is likely to be an excellent target for antiviral drugs. Recently, tetherin was identified as a cellular factor that inhibits the release of HIV-1 from infected cells (Neil et al., 2008 ). It appears to prevent HIV-1 release by retaining fully formed progeny virions on the surfaces of infected cells (Neil et al., 2008; Van Damme et al., 2008) . Subsequent studies have shown that human tetherin/BST-2 also inhibits the release of filoviruses, arenaviruses and herpesviruses (Jouvenet et al., 2009; Kaletsky et al., 2009; Mansouri et al., 2009; Sakuma et al., 2009) . With regard to HEV, although it has been reported that monotherapy using interferon or ribavirin inhibits the viral replication in immunocompromised patients with chronic HEV infection following solid-organ transplantation (Haagsma et al., 2010; Kamar et al., 2010) , virtually no approved antiviral drugs are available to prevent or treat HEV-associated diseases. It may therefore be interesting to analyse whether tetherin/BST-2 inhibit the virion release of HEV. A better understanding of the mechanisms whereby viruses recruit cellular factors should aid greatly in the development of this class of therapeutics.
In conclusion, the present study revealed that HEV recruits Tsg101 via its PSAP motif in the ORF3 protein and requires the L-domain function for virion release from infected cells, and that the enzymic activity of Vps4 is involved in virus release. This suggests that, although HEV is known to be a non-enveloped virus, it requires the MVB pathway for its release from infected cells. To support this hypothesis, immune electron microscopy or fluorescence microscopy showing that HEV is indeed in MVB should be performed in future studies.
METHODS
Cell culture. PLC/PRF/5 cells (ATCC CRL-8024) were grown in Dulbecco's modified Eagle medium (Invitrogen) supplemented with 10 % (v/v) heat-inactivated FBS (Hana-Nesco Bio), 100 U penicillin G ml 21 , 100 mg streptomycin ml 21 and 2.5 mg amphotericin B ml
21
(growth medium), at 37 uC in a humidified 5 % CO 2 atmosphere, as described previously (Tanaka et al., 2007) .
Viruses. HEV progenies (1.3610 8 copies ml 21 ) in the culture supernatant of PLC/PRF/5 cells transfected with RNA transcripts of an infectious cDNA clone of a genotype 3 HEV (pJE03-1760F/wt: DDBJ/EMBL/GenBank accession no. AB437316) (Yamada et al., 2009b) were used for virus inoculation at 10 6 copies per well (six-well plate). The pJE03-1760F/wt was obtained from a faecal specimen containing a high load of wild-type HEV (strain JE03-1760F: 2.0610 7 copies ml 21 ), which can replicate efficiently in PLC/PRF/5 cells (Tanaka et al., 2007) .
Plasmids. The expression plasmids for the ORF3 protein, pCI-HEVORF3/wt and pCI-HEVORF3/mutPLAP/LSAL, whose two PSAP motifs of the ORF3 protein were changed to PLAP (aa 86-89) and LSAL (aa 95-98), respectively, were reported previously (Nagashima et al., 2011; Takahashi et al., 2008b) : all known HEV strains harbour PSAP motif at aa 95-98, while some of the HEV genotype 3 strains, including JE03-1760F, possess an additional PSAP motif at aa 86-89. Plasmids that express Myc-tagged Tsg101 (pBj-Myc-Tsg101) and Flag-tagged Vps4 [pVps4A, pVps4B, and DN mutants of pVps4A and pVsp4B, termed pVps4AEQ (E228Q) and pVps4BEQ (E235Q), respectively] were also described previously (Urata et al., 2006 (Urata et al., , 2007 Yasuda et al., 2003) .
Protein expression and co-immunoprecipitation. PLC/PRF/5 cells were transfected with pBj-Myc-Tsg101 and pCI-HEVORF3/wt or pCI-HEVORF3/mutPLAP/LSAL using the TransIT-LT1 reagent (Mirus Bio) according to the manufacturer's recommendations. Both empty vectors [pBj-Myc vector (Yasuda et al., 2003) and pCI vector (Takahashi et al., 2008b) ] were used as negative controls. At 48 h after transfection, co-immunoprecipitaion assays were performed using an immunoprecipitation kit (Protein G; Roche) according to the manufacturer's recommendations. After clarification by centrifugation, cell lysates were used for immunoprecipitation with an anti-Myc mAb (9E10; Santa Cruz Biotechnology) or anti-ORF3 mAb (TA0536) (Takahashi et al., 2008b) . The co-immunoprecipitated proteins (Tsg101-Myc and ORF3/wt or ORF3/mutPLAP/LSAL) were separated by 10 or 15 % SDS-PAGE, followed by Western blotting analysis with an anti-Tsg101 mAb (C-2; Santa Cruz Biotechnology) or anti-ORF3 mAb, respectively. These proteins were visualized by chemiluminescence using the Clean-Blot IP Detection Reagent (HRP) (Thermo Scientific).
Immunofluorescence assay. PLC/PRF/5 cells in a four-well chamber slide (Nunc) were transfected with 0.5 mg each of pBjMyc-Tsg101 and pCI-HEVORF3/wt or pCI-HEVORF3/mutPLAP/ LSAL using the TransIT-LT1 reagent (Mirus Bio) according to the manufacturer's instructions. The pBj-Myc and pCI vectors were used as negative controls. For staining of the transfected cells, anti-Myc (9E10) and anti-ORF3 (TA0536) mAbs were used to label cells by using the Zenon Alexa Fluor-488 mouse IgG 1 and Zenon Alexa Fluor-594 mouse IgG 2a labelling kits (Molecular Probes), respectively, according to the manufacturer's instructions. For staining of CD63 in the HEV-infected cells, anti-CD63 polyclonal antibody (H-193; Santa Cruz Biotechnology) labelled by using the Zenon Alexa Fluor-488 rabbit IgG labelling kit (Molecular Probes) was used 48 h posttransfection, cells were fixed in 4 % paraformaldehyde at room temperature for 15 min and permeabilized in PBS containing 0.2 % (v/v) Triton X-100 at room temperature for 10 min. Non-specific binding was blocked with 1 % (w/v) BSA in PBS at room temperature for 30 min. Zenon labelling complexes were diluted to a final dilution of 1 : 50 for both primary antibodies, and were applied to the cells at room temperature for 2 h. The nuclei were counterstained with 49,6-diamidino-2-phenylindole (DAPI; Roche). The stained cells were viewed under a FV1000 confocal laser microscope (Olympus). In the quantification of co-localized cells (mean±SE), at least 20 cells were used for calculations in each of two independent experiments.
RNA interference. The following siRNAs were obtained from Dharmacon and used in the present study: human Tsg101 (siGENOME SMARTpool M-003549-01-0005) and control siRNA (siGENOME Non-Targeting siRNA Pool #1 D-001206-13-05). The PLC/PRF/5 cells were seeded at a density of 6.0610 4 cells per well of a 24-well plate (BD Falcon) in antibiotic-free growth medium. The cells were transfected with 5 nM (final concentration) siRNA in Opti-MEM (Gibco/Invitrogen) using DharmaFECT 1 (Dharmacon) according to the manufacturer's instructions, 2 days before and 4 days after virus inoculation.
Plasmid transfection. To analyse the effects of overexpression of Vps4 DN mutants, PLC/PRF/5 cells (6.0610 4 cells per well) in 24-well plates were transfected with 0.5 mg of the expression plasmids for wild-type Vps4 (Vps4A or Vps4B) or their DN mutants (Vps4AEQ or Vps4BEQ) using TransIT-LT1 (Mirus Bio) according to the manufacturer's instructions, 2 days before and 2 and 6 days after virus inoculation. The empty vector, pCDNFL, which was constructed from pcDNA3.1 (Invitrogen) to express a protein containing a FLAG tag at the N terminus, was used as a control.
Virus inoculation. Monolayers of PLC/PRF/5 cells in 24-well plates, which were pretreated with siRNA against Tsg101, or the DN forms of Vps4A and Vps4B as described above, were inoculated with 2.0610 5 copies of HEV progenies in the culture supernatant of pJE03-1760F/ wt RNA-transfected cells. After incubation at room temperature for 1 h, the cells transfected with siRNA or expression plasmids for Vps4A, Vps4B and their derivatives were washed with PBS, 0.5 ml of antibiotic-free or complete growth medium, respectively, was added to each well, and the cells were incubated at 37 uC. Every other day, half of the culture medium (0.25 ml) of siRNA-or Vps4 plasmidtransfected cells was replaced with antibiotic-free or complete growth medium, respectively. The collected culture medium was centrifuged at 1300 g at room temperature for 2 min and the supernatant was stored at 280 uC until use.
Western blotting analysis. The transfected cells were lysed in lysis buffer [50 mM Tris/HCl (pH 8.0), 1 % NP-40, 150 mM NaCl and protease inhibitor cocktail (Sigma)], and proteins in the cell lysates were separated by SDS-PAGE. The proteins were blotted onto PVDF (0.45 mm; Millipore), immunodetected with an anti-HEV ORF3 (TA0536), anti-Myc (9E10), anti-Tsg101 (C-2), anti-Flag (FLAG M2; Sigma) or anti-b-actin (Sigma-Aldrich) mAb, and then visualized by chemiluminescence, as described previously (Yamada et al., 2009b) .
Quantification of HEV RNA. RNA extraction from culture supernatants was performed using the TRIzol-LS Reagent (Invitrogen). Intracellular RNA was extracted from cultured cells using the TRIzol Reagent (Invitrogen). The quantification of HEV RNA was performed by real-time reverse transcription (RT)-PCR using a LightCycler apparatus (Roche), with a QuantiTect Probe RT-PCR kit (Qiagen) and two sets of primers and a probe targeting the ORF2 and ORF3 overlapping region or the ORF1 region, as described previously (Takahashi et al., 2008a; Yamada et al., 2009a) . Unless otherwise stated, the quantification of HEV RNA was performed using the realtime RT-PCR method with the primers and probe derived from the ORF2/ORF3 overlapping region.
